Atlas Selected as the Search and Rescue Unmanned Aerial System for Norwegian Arctic SAR Unit NPAID
Atlas, a global leader in autonomous unmanned aerial systems (UAS) operating in the U.S., U.K. and EU, announced it has been chosen as a UAS provider for the Norwegian People’s Aid (NPAID) Search and Rescue (SAR) Mid-Troms unit, due to its unique capabilities in extreme conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005376/en/
AtlasPRO operation in NPAID’s Arctic SAR Training (Photo: Business Wire)
The NPAID Mid-Troms unit is a volunteer SAR unit operating in northern Norway specializing in first response and lifesaving operations in extreme Arctic environments. The unit covers a region of Arctic Norway famous for its sparsely populated mountain ranges and Fjords. The NPAID team ensures the safety of tourists in the region, especially as adventure tourism continues to increase.
As a highly sophisticated and professional task force, NPAID Mid-Troms is an early adopter of new technologies and its project team is constantly seeking tools aimed at optimizing SAR operations. The team selected Atlas as its UAS provider and uses the AtlasPRO in its missions. Due to its unsurpassed capabilities and reliability, the AtlasPRO is transforming SAR operations in extreme Arctic conditions.
Atlas redefines “man-unmanned teaming” with its robust UAS solutions, designed to be a force multiplier for first responders on the ground. The solutions enable consistent lifesaving operations in extreme conditions, including Arctic weather scenarios. The AtlasPRO drone can operate autonomously, enabling the operator to focus solely on search and rescue, and is being used by different SAR forces in NATO countries.
“Working on lifesaving operations in extreme environments means that every minute counts. Our volunteers require a unique set of skills, but also the best working tools that can deliver fast and accurate results through every mission and challenge, especially during cold temperatures and the winter darkness period, at remote sites and off-grid no-connectivity locations,” said Kenneth Brattli Molund, unit leader and RPAS project SAR technology integration manager at NPAID in Mid-Troms. “We have chosen the AtlasPRO for its ability to withstand and deliver unique sensor setups and operate in harsh conditions, and also due to Atlas’ capabilities as a technology design-house, that allow us to dream bigger and co-design better, faster and safer SAR solutions.”
Atlas’ award-winning MESH communication capabilities allow users to operate several UAVs in tandem from one control station, enabling hours of consistent surveillance over a point of interest in a BVLOS scenario. This provides comprehensive situational awareness for team members on the ground using multi-stream capabilities to numerous smart devices. These capabilities result in greater cost-effectiveness for defense and SAR units across the globe.
“We are proud that our technology is changing SAR paradigms and assisting NPAID Mid-Troms’ professional volunteers in these lifesaving operations,” said Ivan Tolchinsky, founder and CEO at Atlas. “By enabling a robust drone that provides consistent data in every terrain or weather condition, the AtlasPRO fulfills our company vision to save lives.”
Later this year, Atlas and NPAID Mid-Troms are scheduled to reveal a new product that will change the paradigm of avalanche SAR operations and will enable UAS capabilities that have never been used before.
Atlas is a world-leading aerospace company that is redefining the unmanned industry with smart, connected and cost-effective unmanned aerial systems. Atlas robust drones can be operated autonomously enabling the operator to focus on mission objectives. Atlas’ proprietary and award-winning multi-point communication technology, AtlasMESH, is enhanced with artificial intelligence, enabling operation of drone fleets that result in smart mission distribution, flight optimization and data understanding. The company designs and manufactures its product in the E.U. and provides its technology to leading NATO governments, first responders, and multibillion-dollar corporations in the fields of security and industry. https://www.atlasdynamics.eu/
NAS - Norse Asset Solutions is the in-country Atlas system representative and project solution partner towards NPAID. NAS offers and supplies Atlas systems for Norway and Scandinavia. www.NorseAssetSolutions.com
NPAID (Norsk Folkehjelp) division Mid-Troms is a local and geographical entity part of an international large organisation working on supporting and solving demanding missions that are in challenging environments. NPAID have the following main work scopes and tasks; Mine Action and Disarmament, Development Cooperation, First Aid and Rescue Service and Refugees and integration. NPAID Mid-Troms are consisting of Arctic SAR specialists performed by qualified volunteers with unique competency and highest level of commitment easily allowing them to be compared to units and capacity consisting of full-time and professional SAR (Search and Rescue) units. https://www.npaid.org/ - https://folkehjelp.no/lokallag/midt-troms
John Pascarella, firstname.lastname@example.org (on behalf of Atlas)
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
A Continuous Journey of Digital Transformation, Alibaba Cloud and Its Global Customers at Apsara 202018.9.2020 05:00:00 CEST | Press release
As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times. Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud. “It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, A
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer18.9.2020 00:05:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which takes place on September 19-21. “We are pleased to share the promising RATIONALE 304 results, which were used to support our recently accepted supplemental new drug application in first-line non-squamous NSCLC in China,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “BeiGene is evaluating tislelizuma